晨光生物(300138) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥1,732,327,232.51, a decrease of 4.71% compared to ¥1,817,862,277.48 in the same period last year[4] - Net profit attributable to shareholders was ¥38,591,936.61, down 71.42% from ¥135,043,557.83 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥48,487,180.98, a decrease of 58.38% compared to ¥116,513,389.85 in the previous year[4] - In Q1 2024, the company reported a revenue of 1.732 billion CNY, a year-on-year decrease of 4.71%, and a net profit attributable to shareholders of 39 million CNY, down 71.42% year-on-year[24] - Total operating revenue for the current period is ¥1,732,327,232.51, a decrease of 4.7% compared to ¥1,817,862,277.48 in the previous period[30] - Net profit for the current period is ¥32,993,385.92, a significant decline of 76.6% from ¥139,942,815.94 in the previous period[31] - Basic and diluted earnings per share for the current period are both ¥0.0725, down from ¥0.2535 in the previous period[32] - The company reported a total comprehensive income of ¥33,560,393.96, down from ¥150,501,499.27 in the previous period[32] Cash Flow and Assets - The net cash flow from operating activities increased by 245.33%, reaching ¥197,431,523.85, compared to a negative cash flow of ¥135,845,984.90 in the same period last year[4] - The company’s cash and cash equivalents increased to approximately 2.134 billion CNY from 1.422 billion CNY at the beginning of the period[27] - Cash and cash equivalents at the end of the period amount to ¥2,218,585,909.30, up from ¥1,162,353,288.36 in the previous period[34] - Total assets at the end of the reporting period were ¥9,080,731,321.01, an increase of 6.34% from ¥8,539,580,495.63 at the end of the previous year[4] - Total assets rose to approximately 9.081 billion CNY, compared to 8.540 billion CNY at the beginning of the period[29] Investment and Financing - Investment income increased by 209.28% year-on-year, primarily due to higher profits from joint ventures and associates[10] - The company’s long-term borrowings increased by 36.06% compared to the beginning of the period, reflecting a higher financing scale[9] - The company’s interest expenses rose by 31.58% year-on-year, attributed to increased financing needs[9] - Cash outflow related to financing activities decreased by 32.74% year-on-year, primarily due to a reduction in financing through pledged certificates of deposit, with the current period mainly reflecting cash outflow from share repurchases[16] - Net cash flow from investing activities is ¥472,134,216.37, an increase from ¥73,493,457.97 in the previous period[34] Shareholder Information - As of March 31, 2024, the total number of ordinary shareholders was 16,402, an increase from 14,771 at the end of January 2024[19] - The largest shareholder, Lu Qingguo, holds 18.43% of the shares, amounting to 98,196,051 shares, with 73,647,038 shares pledged[18] - The top ten shareholders collectively hold significant stakes, with the second-largest shareholder, Li Yuezhai, owning 3.01% or 16,053,365 shares, also pledged[18] - The company repurchased a total of 20,172,808 shares as of March 31, 2024[19] - The total number of restricted shares at the end of the period was 84,786,801, with 1,527,000 shares released from restriction during the period[22] - The company has commitments from executives not to transfer their shares for six months after leaving their positions, with specific limits on future transfers[23] - The company continues to monitor shareholder relationships and potential impacts on shareholding structures[19] Business Operations - Revenue from traditional plant extraction business (natural pigments/spices/nutrition and sweeteners) was 762 million CNY, showing a slight increase, while gross profit decreased by 1%[24] - The cottonseed business generated revenue of 840 million CNY, a decrease of approximately 12%, with gross profit declining by about 122%[24] - Sales of chili red pigment reached 368 tons in Q1, a significant year-on-year increase, while lutein sales exceeded 80 million grams, indicating a recovery in volume[24] - The company achieved a 50% increase in sales of Sichuan pepper extract and an 11% increase in stevia sales volume, despite revenue decline due to price impacts[25] - The company reported a significant decline in gross margin for the cottonseed processing business due to intensified industry competition and fluctuations in commodity prices[26] - The company is actively expanding its market presence and enhancing product competitiveness through project construction and capacity expansion in the nutritional medicinal extraction sector[25] Research and Development - Research and development expenses increased to ¥23,149,384.73 from ¥17,814,917.96 in the previous period, reflecting a focus on innovation[31]